Krystal Biotech, Inc. (KRYS)

Krystal Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	462.84	496.3	344.87	358.33	161.9	341.25
Short-Term Investments	449.01	331.49	252.65	173.85	217.27	96.85
Cash & Short-Term Investments	911.85	827.79	597.52	532.18	379.17	438.1
Cash Growth	24.73%	38.54%	12.28%	40.35%	-13.45%	61.50%
Receivables	133.12	127.43	104.75	42.04	-	-
Inventory	50.79	40.48	26.51	6.99	-	-
Prepaid Expenses	26.01	28.91	13.27	6.71	4.61	4.17
Total Current Assets	1,122	1,025	742.05	587.91	383.78	442.27
Property, Plant & Equipment	158.9	158.02	161.45	168.23	169.73	119.58
Long-Term Investments	282.3	128.07	152.11	61.95	4.62	64.37
Long-Term Deferred Tax Assets	22.82	22.82	-	-	-	-
Other Long-Term Assets	0.27	0.29	0.23	0.26	0.32	0.07
Total Assets	1,586	1,334	1,056	818.36	558.45	626.3

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6.73	3.24	4.99	4.13	3.98	8.4
Accrued Expenses	111.76	81.25	52.78	18.15	11.54	6.52
Current Portion of Leases	1.82	1.77	1.22	1.47	1.56	1.04
Current Income Taxes Payable	16.87	10.92	4.29	1.96	0.04	0.08
Other Current Liabilities	4.97	5.77	38.73	7.38	11.72	9.69
Total Current Liabilities	142.14	102.94	102	33.09	28.85	25.74
Long-Term Leases	6.77	7.57	6.04	6.62	7.37	6.98
Other Long-Term Liabilities	1.56	3.72	1.42	-	-	-
Total Liabilities	150.47	114.23	109.46	39.71	36.22	32.72

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Additional Paid-In Capital	1,247	1,194	1,127	1,048	803.72	734.52
Retained Earnings	197.93	24.16	-180.67	-269.83	-280.76	-140.78
Comprehensive Income & Other	-9.24	1.14	-0.19	0.64	-0.73	-0.16
Total Common Equity	1,436	1,220	946.38	778.64	522.23	593.58
Shareholders' Equity	1,436	1,220	946.38	778.64	522.23	593.58
Total Liabilities & Equity	1,586	1,334	1,056	818.36	558.45	626.3

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	8.59	9.34	7.26	8.09	8.93	8.02
Net Cash (Debt)	1,186	946.52	742.37	586.04	374.86	494.44
Net Cash Growth	38.72%	27.50%	26.68%	56.34%	-24.19%	84.97%
Net Cash Per Share	38.76	31.60	24.96	21.12	14.70	22.28
Filing Date Shares Outstanding	29.63	29.23	28.81	28.29	25.76	25.21
Total Common Shares Outstanding	29.63	29.19	28.79	28.24	25.76	25.21
Working Capital	979.62	921.66	640.05	554.82	354.93	416.53
Book Value Per Share	48.45	41.78	32.87	27.58	20.27	23.55
Tangible Book Value	1,436	1,220	946.38	778.64	522.23	593.58
Tangible Book Value Per Share	48.45	41.78	32.87	27.58	20.27	23.55
Buildings	109.75	109.24	111.44	111.18	-	-
Machinery	40	37.48	34.19	30.49	12.93	6.51
Construction In Progress	9.95	8.11	5.78	7.29	131.33	104.34
Leasehold Improvements	31.67	27.23	25.67	25.07	24.22	5.72

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 8, 2026

Data Sources Report a data error